MA39190B1 - Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments - Google Patents

Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments

Info

Publication number
MA39190B1
MA39190B1 MA39190A MA39190A MA39190B1 MA 39190 B1 MA39190 B1 MA 39190B1 MA 39190 A MA39190 A MA 39190A MA 39190 A MA39190 A MA 39190A MA 39190 B1 MA39190 B1 MA 39190B1
Authority
MA
Morocco
Prior art keywords
medicaments
preparation
imidazolyl derivatives
fused imidazolyl
fused
Prior art date
Application number
MA39190A
Other languages
English (en)
Other versions
MA39190A1 (fr
Inventor
Carmen Almansa-Rosales
José Luis Diaz-Fernandez
Piotr Nieczypor
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA39190A1 publication Critical patent/MA39190A1/fr
Publication of MA39190B1 publication Critical patent/MA39190B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des nouveaux dérivés d'imidazolyle fusionnés ayant une grande affinité avec des récepteurs sigma, en particulier les récepteurs sigma 1, ainsi que leur procédé de préparation, des compositions les comprenant et leur utilisation en tant que médicaments.
MA39190A 2013-12-20 2014-12-18 Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments MA39190B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13384003 2013-12-20
PCT/EP2014/078457 WO2015091795A1 (fr) 2013-12-20 2014-12-18 Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments

Publications (2)

Publication Number Publication Date
MA39190A1 MA39190A1 (fr) 2017-10-31
MA39190B1 true MA39190B1 (fr) 2018-12-31

Family

ID=49998039

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39190A MA39190B1 (fr) 2013-12-20 2014-12-18 Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments

Country Status (18)

Country Link
US (1) US9676784B2 (fr)
EP (1) EP3083628B1 (fr)
JP (1) JP6464171B2 (fr)
KR (1) KR20160095157A (fr)
CN (1) CN105916858B (fr)
AU (1) AU2014368591A1 (fr)
BR (1) BR112016014295A2 (fr)
CA (1) CA2934144A1 (fr)
ES (1) ES2754430T3 (fr)
IL (1) IL246272A0 (fr)
MA (1) MA39190B1 (fr)
MX (1) MX2016008062A (fr)
PH (1) PH12016501169A1 (fr)
RU (1) RU2016126431A (fr)
SG (1) SG11201604878XA (fr)
TN (1) TN2016000254A1 (fr)
UA (1) UA119547C2 (fr)
WO (1) WO2015091795A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994027C (fr) 2015-07-31 2023-10-10 Merck Patent Gmbh Derives heterocycliques bicycliques
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
KR101887993B1 (ko) * 2016-07-27 2018-08-13 주식회사 엘지화학 광경화 수지 조성물 및 이의 용도
CN112010927B (zh) * 2019-05-28 2021-10-26 首都医科大学 Egh及羟甲基修饰的苯并咪唑喹唑啉，其合成，活性和应用
US20260049071A1 (en) * 2022-08-08 2026-02-19 Beyang Therapeutics Co., Ltd. Protein tyrosine kinase inhibitor and medical use thereof
WO2024105225A1 (fr) 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07101959A (ja) * 1993-09-30 1995-04-18 Sankyo Co Ltd １−メチルカルバペネム誘導体
CA2432578C (fr) * 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Derives quinazolone antagonistes de recepteur alpha 1a/b adrenergique
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
WO2006021463A1 (fr) * 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs de récepteurs sigma
EP1634873A1 (fr) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs des récepteurs sigma
EP1847542A1 (fr) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma
EP1982714A1 (fr) * 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-aminés
EP1982987A1 (fr) * 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Dérivés de spiro-pyrano-pyrazole
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
JP2011515403A (ja) * 2008-03-21 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション キノリジジノンｍ１受容体ポジティブアロステリックモジュレータ
EP2468728A1 (fr) * 2010-12-03 2012-06-27 Laboratorios Del. Dr. Esteve, S.A. Dérivés de 2-(1-phényl-4,5,6,7-tétrahydro-1h-indazol-4-yl)éthylamine utiles en tant qu'inhibiteurs de récepteur sigma
EP2548878A1 (fr) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Composés de pyrazolo[3,4-d]pyrimidine, leur préparation et utilisation en tant que ligands sigma

Also Published As

Publication number Publication date
MA39190A1 (fr) 2017-10-31
CA2934144A1 (fr) 2015-06-25
JP2016540817A (ja) 2016-12-28
ES2754430T3 (es) 2020-04-17
KR20160095157A (ko) 2016-08-10
CN105916858A (zh) 2016-08-31
WO2015091795A1 (fr) 2015-06-25
US20160311828A1 (en) 2016-10-27
EP3083628A1 (fr) 2016-10-26
CN105916858B (zh) 2018-09-14
PH12016501169A1 (en) 2016-07-18
TN2016000254A1 (en) 2017-10-06
AU2014368591A1 (en) 2016-07-07
US9676784B2 (en) 2017-06-13
BR112016014295A2 (pt) 2017-08-08
JP6464171B2 (ja) 2019-02-06
UA119547C2 (uk) 2019-07-10
RU2016126431A (ru) 2018-01-25
EP3083628B1 (fr) 2019-08-07
IL246272A0 (en) 2016-08-02
MX2016008062A (es) 2017-03-09
SG11201604878XA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
EA201600390A1 (ru) КОМПОЗИЦИЯ 1,5-ДИМЕТИЛ-6-ТИОКСО-3-(2,2,7-ТРИФТОР-3-ОКСО-4-(ПРОП-2-ИНИЛ)-3,4-ДИГИДРО-2H-БЕНЗО[b][1,4]ОКСАЗИН-6-ИЛ)-1,3,5-ТРИАЗИНАН-2,4-ДИОНА
MA39190A1 (fr) Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MX374443B (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
MY193249A (en) Anti-human cd19 antibodies with high affinity
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
MX360499B (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
EA201590887A1 (ru) Композиция
FR2983077B1 (fr) Seringue
MY173521A (en) Trpv4 antagonists
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
PE20160190A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
MX374535B (es) Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico.
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
MX373855B (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
BR112017018707A2 (pt) composições compreendendo compostos de mentol como agentes suavizantes
MX358721B (es) Derivados de indeno que tienen afinidad por el receptor sigma, su preparación y su uso como medicamentos.
PH12015502358B1 (en) Highly concentrated formulations of soluble fc receptors